Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Impact of COVID-19 on Japan Active Pharmaceutical Ingredient Market

4.       Executive Summary

5.       Japan Active pharmaceutical ingredient Market Outlook, FY2017-FY2031F

5.1.    Market Size & Forecast

5.1.1.By Value

5.1.2.By Volume

5.2.    By Synthesis

5.2.1.Biotech

5.2.2.Synthetic

5.3.    By Potency

5.3.1.Traditional API

5.3.2.HPAPI

5.4.    By Manufacturer

5.4.1.Captive APIs

5.4.2.Merchant APIs

5.5.    By Type

5.5.1.Generic APIs

5.5.2.Innovative APIs

5.6.    By Drug

5.6.1.Prescription Drugs

5.6.2.Over-the-counter Drugs

5.7.    By Usage

5.7.1.Clinical

5.7.2.Research

5.8.    By Application

5.8.1.Cardiovascular Diseases

5.8.2.Oncology

5.8.3.Neurology

5.8.4.Orthopaedic

5.8.5.Diabetes

5.8.6.Pulmonology

5.8.7.Gastroenterology

5.8.8.Nephrology

5.8.9.Ophthalmology

5.8.10.    Others

5.9.    By Region

5.9.1.North [Hokkaido and Tohoku]

5.9.2.Central [Kanto and Chubu]

5.9.3.South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa].

5.10      By Company Market Share (%), FY2023

6.       Market Mapping, FY2023

6.1.    By Synthesis

6.2.    By Potency

6.3.    By Manufacturer

6.4.    By Type

6.5.    By Drug

6.6.    By Usage

6.7.    By Application

6.8.    By Region

7.       Macro Environment and Industry Structure

7.1.    Supply Demand Analysis

7.2.    Import Export Analysis – Volume and Value

7.3.    Supply/Value Chain Analysis

7.4.    PESTEL Analysis

7.4.1.Political Factors

7.4.2.Economic System

7.4.3.Social Implications

7.4.4.Technological Advancements

7.4.5.Environmental Impacts

7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5.    Porter’s Five Forces Analysis

7.5.1.Supplier Power

7.5.2.Buyer Power

7.5.3.Substitution Threat

7.5.4.Threat from New Entrant

7.5.5.Competitive Rivalry

8.       Market Dynamics

8.1.    Growth Drivers

8.2.    Growth Inhibitors (Challenges, Restraints)

9.       Regulatory Framework and Innovation

9.1.    Clinical Trials

9.2.    Patent Landscape

9.3.    Regulatory Approvals

9.4.    Innovations/Emerging Technologies

10.   Key Players Landscape

10.1.                     Competition Matrix of Top Five Market Leaders

10.2.                     Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)

10.3.                     Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4.                     SWOT Analysis (For Five Market Players)

10.5.                     Patent Analysis (If Applicable)

11.   Pricing Analysis

12.   Case Studies

13.   Key Players Outlook

13.1.                     Pfizer, Inc.

13.1.1.    Company Details

13.1.2.    Key Management Personnel

13.1.3.    Products & Services

13.1.4.    Financials (As reported)

13.1.5.    Key Market Focus & Geographical Presence

13.1.6.    Recent Developments

13.2.                     Cipla Limited

13.3.                     Sun Pharmaceutical Industries Ltd.

13.4.                     AbbVie Inc.

13.5.                     AstraZeneca plc

13.6.                     GlaxoSmithKline plc

13.7.                     Sanofi S.A.

13.8.                     Teva Pharmaceutical Industries Ltd.

13.9.                     Novartis International AG

13.10.                  Boehringer Ingelheim International GmbH

13.11.                  Piramal Enterprises Ltd.

13.12.                  Aurobindo Pharma

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.   Strategic Recommendations

15.   About Us & Disclaimer